Inventiva S.a. Stock News

Daix (France), Long Island City (New York, United States), January 31, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of ora

Daix (France), Long Island City (New York, United States), January 20, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of ora

Daix (France), Long Island City (New York, United States), le 20 janvier 2022 – Inventiva (Euronext Paris et Nasdaq : IVA), société biopharmaceutique spécialisée dans le développement clinique

Daix (France), Long Island City (New York, United States) , January 20, 2022 Inventiva (NASDAQ: IVA ), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs, today announced that the Company''s leadership will participate in two upcoming conferences in January and February 2022. The event details are as follows: Conference n°1: 10 th Edition of Degroof Petercam''s Healthcare Conference Event type: One-on-one investors meetings Date: Thursday, January 27, 2022 Format: Virtual event Conference n°2: 11 th Annual SVB Leerink Global Healthcare Conference Event type: Corporate presentation and one-on-one investors meetings Date: Wednesday, February 16, 2022 Time: 8:40 am (ET) / 2:40 pm (CET) Format: Virtual event Live and replay link: https://wsw.com/webcast/svbleerink67/iva/2427200 The links to these events will also be available on Inventiva''s website in the "Investors Investor Presentations" section.

Daix (France), Long Island City (New York), January 14, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecul

Daix (France), Long Island City (New York), le 14 janvier 2022 – Inventiva S.A. (« Inventiva » ou la « Société ») (Euronext Paris et Nasdaq : IVA), société biopharmaceutique spécialisée da

Daix (France), Long Island City (New York), le 16 décembre 2021 – Inventiva (Euronext Paris et Nasdaq : IVA), société biopharmaceutique spécialisée dans le développement clinique de petites mo

Daix (France), Long Island City (New York), December 16, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecu

Daix (France), Long Island City (New York), December 16, 2021 Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that Frédéric Cren, Chairman, CEO and cofounder of Inventiva, has been invited to present a corporate overview, followed by a Q&A session, and will engage, with Inventivas leadership team, in 1x1 investor meetings at the upcoming 40 th Annual J.P. Morgan Annual Healthcare Conference, being held virtually on January 10-13, 2022.

Inventiva (NYSE:IVA) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a note issued to investors on Wednesday, Zacks.com reports. The brokerage presently has a $15.00 target price on the stock. Zacks Investment Researchs price target indicates a potential upside of 9.49% from the companys current price. According to [] The post Inventiva (NYSE:IVA) Upgraded at Zacks Investment Research appeared first on ETF Daily News .

Inventiva S.A. (NASDAQ:IVA) saw strong trading volume on Monday . 11,600 shares traded hands during trading, a decline of 57% from the previous sessions volume of 26,672 shares.The stock last traded at $14.01 and had previously closed at $13.80. Separately, HC Wainwright increased their price target on Inventiva from $40.00 to $42.00 and gave the []

Inventiva (NASDAQ: IVA ) announced the results of a clinical thorough QT/QTc study demonstrating the safety of lanifibranor on cardiac electrical activity. The assessment of lanifibranor on cardiac repolarization was conducted under FDA in Phase 1 double-blind clinical trial to be … Full story available on Benzinga.com

Inventiva (NASDAQ: IVA) announced the results of a clinical thorough QT/QTc study demonstrating the safety of lanifibranor on cardiac electrical activity. The assessment of lanifibranor on cardiac

Trial conducted in 217 patients to evaluate the potential effect of lanifibranor on the QT/QTc interval in healthy subjects and to support lanifibranor New Drug Application (NDA) package in NASH La

Daix (France), Long Island City (New York, Etats-Unis), le 6 décembre 2021 – Inventiva (Euronext Paris et Nasdaq : IVA), société biopharmaceutique spécialisée dans le développement clinique de